Organon & Co. (NYSE:OGN) Shares Down 3.8% – What’s Next?

Organon & Co. (NYSE:OGN) shares traded down 3.8% during trading on Monday . The stock traded as low as $14.65 and last traded at $14.72. 1,048,407 shares were traded during mid-day trading, a decline of 54% from the average session volume of 2,296,159 shares. The stock had previously closed at $15.30.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the company from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Stock Performance

The business’s fifty day moving average price is $16.33 and its 200-day moving average price is $19.08. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $3.80 billion, a PE ratio of 2.93, a P/E/G ratio of 0.81 and a beta of 0.75.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share. As a group, equities research analysts expect that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.58%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Institutional Trading of Organon & Co.

A number of hedge funds have recently made changes to their positions in the stock. LSV Asset Management raised its position in Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock valued at $136,843,000 after purchasing an additional 2,121,940 shares in the last quarter. Weiss Asset Management LP purchased a new position in shares of Organon & Co. during the 3rd quarter valued at about $32,966,000. AQR Capital Management LLC raised its holdings in shares of Organon & Co. by 39.8% during the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock valued at $71,905,000 after buying an additional 988,336 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Organon & Co. by 303.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after buying an additional 934,505 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after buying an additional 875,128 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.